Codexis, Inc.CDXSNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

prnewswire.com

Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics

REDWOOD CITY, Calif., Jan. 7, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of LGC Group, an oligonucleotide Contract Research Development and Manufacturing organization (CRDMO), today announced that they have entered into an agreement under which Axolabs will evaluate Codexis' ECO Synthesis Manufacturing Platform.

zacks.com

Down 30% in 4 Weeks, Here's Why You Should You Buy the Dip in Codexis (CDXS)

Codexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

globenewswire.com

Codexis Announces Signing of Lease for GMP Manufacturing Facility

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California.

seekingalpha.com

Codexis, Inc. (CDXS) Q3 2025 Earnings Call Transcript

Codexis, Inc. ( CDXS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Georgia Erbez - CFO & Chief Business Officer Stephen Dilly Alison Moore - President, CEO & Director Britton Jimenez Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Tollef Kohrman - Craig-Hallum Capital Group LLC, Research Division Chad Wiatrowski - TD Cowen, Research Division Presentation Operator Greetings, and welcome to the Codexis Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference is being recorded.

zacks.com

Codexis (CDXS) Reports Q3 Loss, Misses Revenue Estimates

Codexis (CDXS) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.29 per share a year ago.

prnewswire.com

Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing

REDWOOD CITY, Calif. , Oct. 29, 2025 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko Avecia, Inc. a leading contract development and manufacturing organization (CDMO) specializing in oligonucleotide therapeutics, today announced that they have entered into an evaluation agreement.

globenewswire.com

Codexis to Report Third Quarter 2025 Financial Results on November 6

REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2025 on Thursday, November 6, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.

globenewswire.com

Codexis to Participate in Cantor Global Healthcare Conference

REDWOOD CITY, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference, being held September 3-5, 2025, in New York, New York.

seekingalpha.com

Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript

Codexis, Inc. (NASDAQ:CDXS ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Georgia L. Erbez - Chief Financial Officer Kevin Norrett - Chief Operating Officer Stephen George Dilly - President, CEO & Chairman Conference Call Participants Allison Marie Bratzel - Piper Sandler & Co., Research Division Brendan Mychal Smith - TD Cowen, Research Division Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Matthew Jay Stanton - Jefferies LLC, Research Division Operator Welcome to Codexis Second Quarter 2025 Earnings Conference Call.

zacks.com

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

Codexis (CDXS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.32 per share a year ago.

globenewswire.com

Codexis Reports Second Quarter 2025 Financial Results

Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM facility and Innovatus loan to support expansion of ECO Synthesis REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.

globenewswire.com

Codexis to Report Second Quarter 2025 Financial Results on August 13

REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the second quarter of 2025 on Wednesday, August 13, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.

globenewswire.com

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases

globenewswire.com

Codexis to Participate in Jefferies Global Healthcare Conference

REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 3-5, 2025, in New York, New York.

seekingalpha.com

Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

Codexis, Inc. (NASDAQ:CDXS ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Executive Officer Georgia Erbez - Chief Financial Officer Stefan Lutz - Senior Vice President of Research Conference Call Participants Kristen Kluska - Cantor Fitzgerald Tycho Peterson - Jefferies Allison Bratzel - Piper Sandler Dan Arias - Stifel Matthew Hewitt - Craig-Hallum Brendan Smith - TD Cowen Operator Greetings and welcome to the Codexis First Quarter 2025 Earnings Conference Call and webcast. At this time, all participants are in a listen-only mode.

zacks.com

Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates

Codexis (CDXS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.16 per share a year ago.

globenewswire.com

Codexis Reports First Quarter 2025 Financial Results

Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual meeting, including three from leading CDMO collaborators REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.

globenewswire.com

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes

globenewswire.com

Codexis to Report First Quarter 2025 Financial Results on May 14

REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the first quarter of 2025 on Wednesday, May 14, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.

zacks.com

Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?

Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance